Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Adamo, Vincenzo [1 ]
Festa, Vincenzo [1 ]
Restuccia, Eleonora [1 ]
Chiofalo, Giuseppe [1 ]
Maisano, Carmelo [1 ]
Picciotto, Maria [1 ]
Alafaci, Elisabetta [1 ]
Tortora, Giampaolo [2 ]
机构：
[1] AO Univ Polyclin G Martino, Dept Human Pathol, Med Oncol & Integrated Therapies Unit, Messina, Italy
[2] Univ Naples Federico 2, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [41] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Lindsay, Sheila
    Nalla, Sneha
    Schwartz, Gabriel
    Whitman, Julia
    Zendejas, Patricia
    Zhang Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [42] Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer
    George, Thomas J.
    Ivey, Alison M.
    Ali, Azka
    Lee, Ji-Hyun
    Wang, Yu
    Daily, Karen C.
    Ramnaraign, Brian H.
    Tan, Sanda A.
    Terracina, Krista P.
    Read, Thomas E.
    Dang, Long H.
    Iqbal, Atif
    ONCOLOGIST, 2021, 26 (05): : 362 - E724
  • [43] Gene expression markers of resistance to capecitabine-oxaliplatin-bevacizumab treatment in metastatic colorectal cancer (mCRC).
    Rodriguez, Nuria
    Cejas, Paloma
    Moreno, Juan
    Mendiola, Marta
    Salud, Antonieta
    Jose Safont, Maria
    Garcia-Giron, Carlos
    Aparicio, Jorge
    Vera, Ruth
    Jorge Fernandez, Monica
    Escudero, Pilar
    Maurel, Juan
    Feliu, Jaime
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal cancer (mCRC)
    Iqbal, S.
    Yang, D.
    Cole, S.
    El-Khoueiry, A. B.
    Boswell, W.
    Agafitei, R.
    Lujan, R.
    Lenz, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
  • [46] Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab.
    Al-Shamsi, Humaid O.
    Anjum, Mahraz
    Al Farsi, Abdulaziz Mohammed
    Shen, Hua
    Cook, Richard J.
    Linkins, Lori-Ann
    Major, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Capecitabine plus irinotecan in combination with bevacizumab in chemonaive metastatic colorectal cancer, pilot study
    Kocakova, I
    Lakomy, R.
    Spelda, S.
    Kocak, I
    Vyzula, R.
    ANNALS OF ONCOLOGY, 2006, 17 : 41 - 41
  • [49] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Chen, E.
    Welch, S.
    Kryzanowska, M.
    Mackay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
  • [50] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Chen, E. X.
    Welch, S.
    Krzyzanowska, M.
    MacKay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345